Get the Stockscreener App
1.80
2.17%
-0.04
Nls Pharmaceutics Ltd stock is traded at $1.80, with a volume of 78,660.
It is down -2.17% in the last 24 hours and down -37.06% over the past month.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$1.84
Open:
$1.79
24h Volume:
78,660
Relative Volume:
0.28
Market Cap:
$6.48M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-3.60
EPS:
-0.5
Net Cash Flow:
$-13.51M
1W Performance:
-9.09%
1M Performance:
-37.06%
6M Performance:
-27.71%
1Y Performance:
-78.34%
1-Day Range:
$1.71
$1.82
1-Week Range:
$1.71
$2.1137
52-Week Range:
$1.30
$9.112
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.80 | 9.03M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
Institutional scanner results for NLS Pharmaceutics AG Equity WarrantAI Trend Detection for Entry Timing - Newser
Volume spikes in NLS Pharmaceutics AG stock – what they meanSmart Entry Watchlist with Daily Analysis - Newser
Does NLS Pharmaceutics AG Equity Warrant stock pay reliable dividendsPredictive System for Long-Term Stock Forecast - Newser
How strong is NLS Pharmaceutics AG company’s balance sheetMarket Forecast Outlook With Proven Results - jammulinksnews.com
Can technical indicators confirm NLS Pharmaceutics AG Equity Warrant’s reversal - Newser
Will NLS Pharmaceutics AG Equity Warrant stock recover after recent dropSwing Entry Risk Mitigation with Chart Analysis - Newser
How NLS Pharmaceutics AG stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
NLS Pharmaceutics (NASDAQ:NLSP) Shares Up 2% – Should You Buy? - Defense World
Sector Leaders Rotate Capital Into NLS Pharmaceutics AGProfit Focused Stock Screener Results Released - metal.it
Published on: 2025-07-28 23:38:35 - metal.it
Risk vs reward if holding onto NLS Pharmaceutics AG Equity WarrantShort-Term Market Movement Forecast Report - Newser
Does NLS Pharmaceutics AG Equity Warrant stock perform well during market downturnsConsistently high yield - jammulinksnews.com
What is the dividend policy of NLS Pharmaceutics AG stockGet timely alerts on market opportunities - jammulinksnews.com
What is the risk reward ratio of investing in NLS Pharmaceutics AG Equity Warrant stockAI Powered Tracker That Work - jammulinksnews.com
Is it the right time to buy NLS Pharmaceutics AG stockUnlock exclusive trading strategies for gains - jammulinksnews.com
Should I hold or sell NLS Pharmaceutics AG Equity Warrant stock in 2025Get daily updates on the hottest stocks - jammulinksnews.com
How does NLS Pharmaceutics AG compare to its industry peersCapitalize on emerging industry trends - jammulinksnews.com
What makes NLS Pharmaceutics AG Equity Warrant stock price move sharplyInvest smarter with data-backed trading alerts - jammulinksnews.com
How volatile is NLS Pharmaceutics AG stock compared to the marketFastest return on investment - jammulinksnews.com
What drives NLS Pharmaceutics AG Equity Warrant stock priceFree Stock Movement Tracking - PrintWeekIndia
Is NLS Pharmaceutics AG a good long term investmentSky-high profits - PrintWeekIndia
What risks could impact NLS Pharmaceutics AG Equity Warrant stock performanceRapid Gain Targets - Newser
What drives NLS Pharmaceutics AG stock priceBreakout portfolio performance - jammulinksnews.com
What analysts say about NLS Pharmaceutics AG Equity Warrant stockTremendous growth opportunities - Autocar Professional
What analysts say about NLS Pharmaceutics AG stockExceptional portfolio growth - jammulinksnews.com
Is NLS Pharmaceutics AG Equity Warrant a good long term investmentPhenomenal capital gains - jammulinksnews.com
NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - The Malaysian Reserve
How NLS Pharmaceutics AG stock reacts to Fed policy changesCapital Protected Stock Selections - Newser
NLS Pharma's Diabetes Treatment Project Gets Fresh Funding Boost From US-Israel Foundation - 富途牛牛
NLS Pharmaceutics Advances iTOL-102 Diabetes Program with BIRD Foundation Support - TipRanks
Bird Foundation Approves Additional Milestone Payment to Kadimastem and Itolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - MarketScreener
NLS Pharmaceutics Highlights Continued Progress in ITOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and ITolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - 富途牛牛
Why NLS Pharmaceutics AG Equity Warrant stock attracts strong analyst attentionFree Smart Money Stock Analysis - Newser
What makes NLS Pharmaceutics AG stock price move sharplyHigh Confidence Trade Setups - Newser
NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen - Defense World
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - Newswire :) Press Release Distribution
NLS Pharmaceutics Gains Shareholder Approval for Strategic Agenda - The Globe and Mail
Why Did NLS Pharmaceutics Soar 13.79%? - AInvest
NLS Pharmaceutics and Kadimastem Closes $1 Million Equity Financing - citybiz
NLS Pharmaceutics Secures $1 Million Through Equity Financing Amendment - TipRanks
NLS Pharmaceutics Soars 10.04% Pre-Market on Investor Optimism - AInvest
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing - PR Newswire
NLS Pharmaceutics Announces Strategic Merger and Financing Milestones - TipRanks
NLS Pharmaceutics CEO Issues Letter to Shareholders - marketscreener.com
NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free - Stock Titan
NLS Pharmaceutics Announces June 2025 Shareholders’ Meeting Amid Financial Losses - TipRanks
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):